A phase II study of Rexmyelocel-T (REX-001) on therapeutic angiogenesis in diabetic patients with non-revascularizable critical limb ischaemia
Latest Information Update: 08 Feb 2022
At a glance
- Drugs Rexmyelocel T (Primary)
- Indications Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Ixaka; Rexgenero
- 22 Jun 2020 Combined results from this and a phase I/II trial, presented in a Rexgenero media release.
- 04 Aug 2016 New trial record